Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity

Hoffman SJ, Sadrolashrafi K, Mobini N. Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity. Case Rep Dermatol Med.[...]

Prediction Markets in Dermatology: Ethical Considerations for Physicians

Jonnalagadda A, Desai AD, Zhou AE, Grant-Kels JM. Prediction Markets in Dermatology: Ethical Considerations for Physicians. Clin Dermatol. 2026 Sep 3:S0738-081X(26)00226-9. doi: 10.1016/j.clindermatol.2026.09.001. Epub ahead[...]

Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults

Gregoire S, Dewey E, Biba U, Sanchez K, Englander H, Salloum L, Ershadi S, Cheng D, McIntosh BA, Zangenah N, Vazquez-Machado M, Parekh A, Kam[...]